Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Nivolumab Combination Improves Outcomes In Older Advanced Hodgkin’s Lymphoma Patients

From the 65th American Society of Hematology Annual Meeting:
Switching from brentuximab vedotin to nivolumab alongside chemotherapy increased progression-free survival and reduced toxicity in patients aged 60 years and older with classic Hodgkin’s lymphoma

Welcome to OncologyPRO – educational and scientific content for ESMO Members. Participants of some ESMO Meetings will have access to the Meeting resources section—limited to the meeting you attended. To gain full access to all the resources on this website, you must be an ESMO Member.

Please sign in using the username and password you created. To ensure a seamless browsing experience, we suggest that you sign in at the start of your visit.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.